Viatris Inc. (BIT:1VTRS)

Italy flag Italy · Delayed Price · Currency is EUR
13.84
+0.32 (2.37%)
At close: May 7, 2026
Market Cap15.80B +97.6%
Revenue (ttm)12.18B -3.0%
Net Income-2.99B
EPS-2.56
Shares Outn/a
PE Ration/a
Forward PE6.52
Dividend0.42 (3.23%)
Ex-Dividend DateMar 6, 2026
Volume416
Average Volume69
Open13.46
Previous Close13.52
Day's Range13.46 - 13.84
52-Week Range7.28 - 13.87
Betan/a
RSI73.12
Earnings DateMay 7, 2026

About Viatris

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]

Industry Pharmaceutical Preparations
Founded 1961
Employees 30,000
Stock Exchange Borsa Italiana
Ticker Symbol 1VTRS

Financial Performance

In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.

Financial numbers in USD Financial Statements

News

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Confer...

7 hours ago - PRNewsWire

Viatris beats quarterly estimates on China strength, branded drug sales

Viatris topped analysts' estimates for first-quarter revenue and profit on Thursday, ​buoyed by strength in its China business and strong demand for ‌branded drugs.

11 hours ago - Reuters

Viatris Earnings Call Transcript: Q1 2026

Q1 2026 delivered 3% revenue growth and 10% adjusted EBITDA growth, led by strong performance in Greater China and North America. Multiple product launches and regulatory milestones are expected in 2026, with disciplined capital allocation and cost optimization supporting future growth.

15 hours ago - Transcripts

Viatris Reports First-Quarter 2026 Financial Results

Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to ...

17 hours ago - PRNewsWire

Viatris Announces Quarterly Dividend

PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and out...

2 days ago - PRNewsWire

Viatris Announces Chief Financial Officer Transition

Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "D...

3 days ago - PRNewsWire

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contrace...

6 days ago - PRNewsWire

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Compa...

24 days ago - PRNewsWire

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refra...

27 days ago - PRNewsWire

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

5 weeks ago - Benzinga

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, tod...

6 weeks ago - PRNewsWire

Viatris Transcript: Investor update

A focused transformation has positioned the company for sustainable growth, targeting 5%-6% revenue and 7%-8% EBITDA growth by 2030, with over $11B in capital for deployment. Key drivers include a robust pipeline, disciplined business development, and operational efficiencies.

7 weeks ago - Transcripts

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxic...

7 weeks ago - PRNewsWire

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research

Generic drugmaker Viatris has settled a lawsuit brought by the family of Henrietta Lacks, a Maryland woman whose tissue samples were ​used without her permission to develop enduring cells for lucrativ...

2 months ago - Reuters

These S&P 500 stocks are falling the hardest on Tuesday

Stocks of gold miners and computer-memory makers were hit especially hard, while Best Buy led the S&P 500 with a gain after its earnings report.

2 months ago - Market Watch

AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.

It can seem like a nothing-to-buy market. But there are solid stocks out there.

2 months ago - Barrons

Viatris forecasts 2026 profit below estimates on India manufacturing woes

Drugmaker Viatris forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.

2 months ago - Reuters

Viatris Earnings Call Transcript: Q4 2025

2025 saw 2% revenue growth and strong pipeline progress, with $14.3B in revenue and $4.2B Adjusted EBITDA. Strategic review identified $650M in cost savings, supporting 2% growth guidance for 2026 and multiple product launches. Over $1B was returned to shareholders.

2 months ago - Transcripts

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Reports Fourth-Quarter Total Revenues of $ 3.7B and Full-Year 2025 Total Revenues of $ 14.3B Meets or Exceeds 2025 Financial Guidance Across All Key Metrics[1] Returns More Than $1B to Shareholders in...

2 months ago - PRNewsWire

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share an...

2 months ago - PRNewsWire

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administrat...

2 months ago - PRNewsWire

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depo...

2 months ago - GlobeNewsWire

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, Febru...

3 months ago - PRNewsWire

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) anno...

3 months ago - PRNewsWire

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today anno...

3 months ago - PRNewsWire